LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)

The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Li Fraumeni Syndrome Congenital, Hereditary, and Neonatal Diseases and Abnormalities DNA Repair-Deficiency Disorders Genetic Diseases, Inborn Li-Fraumeni Syndrome Metabolic Diseases Neoplasms Neoplastic Syndromes, Hereditary Nutritional and Metabolic Diseases

Age range

5 year–71 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Institut Gustave Roussy

Villejuif, 94805, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

P53 mutation

Treatment and study plan

Whole body MRI

Other

whole body MRI at inclusion, one and two years

Primary outcomes

cancer incidence

Time frame: 3 years

cancer incidence during the first 3 years

Sponsors and collaborators

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Other

Registry information

Acronym: LIFSCREEN

Important dates

Study start: 2011
Primary completion: 2017
Study completion: 2017
First posted: Nov 3, 2011
Registry last updated: Feb 25, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting